Published in Drug Week, September 8th, 2006
"Although resting B cells are known for being poorly immunogenic and for inducing T-cell tolerance, we have attempted to test whether their immunogenicity could be enhanced by CD1d-restricted invariant T cells (iNKT) to a point where they could be used in cellular vaccines," scientists in South Korea report.
"We found that the addition of the iNKT ligand alpha-galactosylceramide (alpha GalCer) to peptide-loaded B cells overcame peptide-specific T-cell unresponsiveness and allowed for the generation of peptide-specific memory CTL immunity," said...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.